ElevateBio and AgBiome Announce Life Edit Will Join ElevateBio’s Portfolio


ElevateBio and AgBiome Announce Life Edit Will Join ElevateBio’s Portfolio

Cambridge, Mass. and Research Triangle Park, NC – November 16, 2020 - ElevateBio, aCambridge-based cell and gene therapy holding company, and AgBiome, a leader in developing innovative products from the Earth's microbial communities, today announced that Life Edit Therapeutics has joined ElevateBio’s growing portfolio of therapeutic, technology and manufacturing companies. Life Edit Therapeutics combines a highly innovative genome editing platform, derived from AgBiome’s massive proprietary microbial library, with ElevateBio’s proven expertise in the discovery and development of new cell and gene therapies. Life Edit will continue to develop internal cell and gene therapies while further strengthening its platform of diverse genome-editing enzymes and provide gene editing expertise to strategic partners including ElevateBio portfolio companies. AgBiome retains rights for gene editing in agriculture, animal health, and diagnostics.“Genome editing technologies have revolutionized the way we develop cell and gene therapies and regenerative medicines,” said Mitchell Finer, Ph.D., President, ElevateBio BaseCamp, and newly appointed Chief Executive Officer, Life Edit Therapeutics. “However, in order to realize the promise of, and democratize, these highly innovative therapeutic approaches, the field needs to access novel RNA-guided nucleases and base editors that offer greater specificity and broader genome coverage, which Life Edit can provide. Life Edit genome editing platform is one of the most versatile in the field and was the natural fit as we continue to build a world leading cell and gene therapy offering.”

View the Full Press Release